Cytochrome P450 family 19 subfamily A member 1 (Aromatase) (CYP19A1)

Cytochrome P450 family 19 subfamily A member 1, widely known as aromatase, is the key enzyme responsible for the final and rate-limiting step in estrogen biosynthesis. It catalyzes the conversion of C19 androgens, such as testosterone and androstenedione, into C18 estrogens, including estradiol and estrone, through a series of three hydroxylation reactions (UniProt P11511). This enzyme is primarily localized in the endoplasmic reticulum of various tissues, including the ovaries, placenta, adipose tissue, and brain, where it plays a fundamental role in sexual differentiation and reproductive health (NCBI Gene 1588). In clinical oncology, CYP19A1 is a premier therapeutic target for hormone-receptor-positive (ER+) breast cancer in postmenopausal women, as its inhibition effectively starves estrogen-dependent tumors of their primary growth stimulus (StatPearls NBK557856). Beyond its enzymatic activity, the regulation of CYP19A1 expression and protein stability is a critical factor in diseases like endometriosis and aromatase excess syndrome, where overproduction of estrogen leads to pathological states (PubMed 25682126). Current pharmacological strategies utilize aromatase inhibitors (AIs), which are classified as either non-steroidal reversible inhibitors (e.g., letrozole) or steroidal irreversible inactivators (e.g., exemestane). Emerging research also explores the modulation of CYP19A1 protein stability through ubiquitin-proteasome pathways as a potential strategy to overcome resistance to traditional inhibitors (PubMed 31201214).

Other names

AromataseEstrogen synthaseCYP19P450AROMCytochrome P450 19A1

Inhibition of aromatase enzyme activity to prevent the conversion of androgens to estrogens, thereby reducing circulating estrogen levels.